Peer-reviewed veterinary case report
Lomustine and prednisolone as first treatment for dog lymphoma
By Catalucci, Chiara et al.·Published in Veterinary and comparative oncology·2024·Oncology Service, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of Lomustine and Prednisolone as First-Line Treatment in Canine Multicentric Lymphoma.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with multicentric lymphoma (a type of cancer affecting the lymph nodes) were treated with lomustine and prednisolone, two medications commonly used for this condition. Out of 30 dogs, about 87% responded to the treatment, with half achieving complete remission. However, the average time before the cancer progressed again was only about 42 days, and the overall survival time was around 90 days. This suggests that while the treatment can help manage symptoms, it may not be effective for long-term control of the disease.
People also search for: dog lymphoma treatment options · lomustine for dogs · prednisolone side effects in dogs
Abstract
Multiagent chemotherapy is considered the most effective treatment for canine high-grade lymphoma; however, due to cost and time requirements, single-agent protocols have also been described. The aim of our study was to evaluate the outcome and prognostic factors of dogs affected by multicentric lymphoma treated with lomustine and prednisolone as first-line treatment. Cases of medium-large-cell multicentric lymphoma treated with lomustine and prednisolone were included in the study. Response to therapy, time to progression (TTP), median disease-free interval (MDFI) and median survival time (MST) were retrospectively described. Thirty cases were included. Eleven (36.67%) were T cell, 11 (36.67%) were B cell and 8 (26.66%) had unknown immunophenotype. The overall response rate (RR) was 87%, with 15 patients achieving CR (50%) and 11 patients PR (37%). The median TTP, MDFI and MST were 42, 63 and 90 days, respectively. The only factor significantly associated with MDFI and MST was the stage. Dogs with multicentric lymphoma treated with lomustine and prednisolone have lower RR, TTP, MDFI and MST compared with dogs receiving multiagent protocols. Based on the short-lasting response, this study confirms that this protocol might have minimal utility beyond palliation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38890811/